Anand Rohatgi, MD
Cardiovascular Disease · Dallas, TXNPI 1427173533
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 4 manufacturers reported payments, led by Amgen at 54.7% of the total. Reporting peaked in 2022 at $8,184 and has fallen 81.5% since, to $1,514 in 2023.
Across 9 payments — averaging $1247.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$6K
- CSL Behring$4K
- Janssen Scientific Affairs, LLC$2K
- Lilly USA, LLC$14
Across 2 payments — averaging $63,035 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$126K
What the payments were for
- Consulting fees$3,55032%
- Speaking & faculty fees$6,52458%
- Travel & lodging$1,13510%
- Food & beverage$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 5 | $6,140 |
| CSL Behring | 2 | $3,569 |
| Janssen Scientific Affairs, LLC | 1 | $1,500 |
| Lilly USA, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KRYSTEXXA$6,134
How this compares
$11,223 in reported general payments places this provider in the 80th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 26 | $34,608 |
| Repatha SureclickEvolocumab | 35 | $25,519 |
| NexletolBempedoic Acid | 11 | $4,235 |
| Rosuvastatin Calcium | 78 | $1,413 |
| Ezetimibe | 35 | $1,236 |
| Atorvastatin Calcium | 34 | $411 |
| Metoprolol Succinate | 26 | $286 |
| Amlodipine Besylate | 21 | $182 |
| Furosemide | 14 | $162 |
| Carvedilol | 12 | $159 |
| Metoprolol Tartrate | 11 | $99 |
| Spironolactone | 12 | $56 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Dallas
- Ramin Farzaneh-FarDallas$17.1M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
- Ambarish PandeyDallas$325K
- Eric PetersonDallas$187K
- Brittany WeberDallas$186K
- James de LemosDallas$181K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.